|
1 Indications And Usage Kisqali Is Indicated In Combination With: An Aromatase Inhibitor For The Treatment Of Pre/perimenopausal Or Postmenopausal Women, With Hormone Receptor (Hr)-Positive, Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Advanced Or Metastatic Breast Cancer, As Initial Endocrine-Based Therapy; Or Fulvestrant For The Treatment Of Postmenopausal Women With Hr-Positive, Her2-Negative Advanced Or Metastatic Breast Cancer, As Initial Endocrine-Based Therapy Or Following Disease Progression On Endocrine Therapy. Kisqali Is A Kinase Inhibitor Indicated In Combination With: An Aromatase Inhibitor For The Treatment Of Pre/perimenopausal Or Postmenopausal Women With Hormone Receptor (Hr)-Positive, Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Advanced Or Metastatic Breast Cancer, As Initial Endocrine-Based Therapy; Or Fulvestrant For The Treatment Of Postmenopausal Women With Hr-Positive, Her2-Negative Advanced Or Metastatic Breast Cancer, As Initial Endocrine-Based Therapy Or Following Disease Progression On Endocrine Therapy. ( 1 )
|